Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 908 participants.

Also called NCT03684642

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 908 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03684642
  • EudraCT 2017-002956-10
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Hungary, Poland, Ukraine (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03684642. Randomized; no masking; primary purpose treatment. Start 2018-09-26 (actual); primary completion 2020-10-13 (actual). Results posted on 2021-11-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
Acronym
AMPLITUDE-D
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Efpeglenatide
Intervention (Drug)
Dulaglutide
Intervention (Drug)
Background therapy Metformin
Lead sponsor
Sanofi (class: industry)
Collaborator
Hanmi Pharmaceutical Company Limited (class: industry)

Record details

Record id
cardio:ct-nct03684642
Content hash
3292ea00ed3e1ecacc6aef3722344f88142d9b424319c2de91389b2e42a66d2c